Melanoma brain metastasis pseudoprogression after pembrolizumab treatment

Cancer Immunology Research

Volumn 4, Issue 3, 2016, Pages 179-182

  Cohen, Justine V ^a   Alomari, Ahmed K ^a   Vortmeyer, Alexander O ^a   Jilaveanu, Lucia B ^a   Goldberg, Sarah B ^a   Mahajan, Amit ^a   Chiang, Veronica L ^a   Kluger, Harriet M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; GADOLINIUM; HMB45 PROTEIN; IPILIMUMAB; MELAN A; PEMBROLIZUMAB; PROTEIN; PROTEIN S 100; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ASTROCYTOSIS; BRAIN DAMAGE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CD8+ T LYMPHOCYTE; DISEASE COURSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTATIC MELANOMA; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; SUBCUTANEOUS TISSUE; TREATMENT DURATION; BRAIN NEOPLASMS; MELANOMA; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84962016032     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0160     Document Type: Article

References (25)

1. Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, et al. Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer 2011;35:200-10.
2. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010;102:1213-8.
3. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22:1293-300.
4. Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, Leachman SA, et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 2007;110:1329-37.
5. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 2009;16:248-55.
6. Margolin K. Ipilimumabin a phase II trial of melanoma patients with brain metastases. Oncoimmunology 2012;1:1197-9.
7. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, etal. Ipilimumab and fotemustineinpatients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012;13:879-86.
8. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenibinpatientswithmelanoma, untreatedbrainmetastases, andother solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-901.
9. Siena S, Crino L, Danova M, Del Prete S, Cascinu S, Salvagni S, et al. Dosedense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010;21:655-61.
10. Amaravadi RK, Schuchter LM, McDermottDF, KramerA, GilesL, GramlichK, et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients withorwithout brain metastases. Clin Cancer Res 2009;15:7711-8.
11. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-95.
12. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990;66:1873-8.
13. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25.
14. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-7.
15. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459-65.
16. Hodi FS, O'DaySJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumabinpatients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
17. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010;120:1368-79.
18. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 2011;8:4.
19. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013;2:899-906.
20. Tazi K, Hathaway A, Chiuzan C, Shirai K. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 2015;4:1-6.
21. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanomabrain metastasesinthe ipilimumab eraandthe possibility of longer survival. J Neurosurg 2012;117:227-33.
22. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 2013;23:191-5.
23. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008;5:557-61.
24. Nath SK, Sheridan AD, Rauch PJ, Yu JB, Minja FJ, Vortmeyer AO, et al. Significance of histology in determining management of lesions regrowing after radiosurgery. J Neurooncol 2014;117:303-10.
25. Rauch PJ, Park HS, Knisely JP, Chiang VL, Vortmeyer AO. Delayed radiation-induced vasculitic leukoencephalopathy. Int J Radiat Oncol Biol Phys 2012;83:369-75.